1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. BOTULINUM TOXINS MARKET BY TYPE
5.1. Introduction
5.2. Botulinum Toxin Type A
5.3. Botulinum Toxin Type B
6. BOTULINUM TOXINS MARKET BY APPLICATION
6.1. Introduction
6.2. Aesthetic Application
6.3. Therapeutic Application
7. BOTULINUM TOXINS MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Cosmetic Centers
8. BOTULINUM TOXINS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Indonesia
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Allergan Aesthetics (an AbbVie company)
10.2. Galderma S.A.
10.3. Revance Therapeutics, Inc.
10.4. Ipsen Pharma
10.5. Merz Pharma
10.6. Medytox Inc.
10.7. Hugel, Inc.
10.8. Daewoong Pharmaceutical Co., Ltd.
10.9. Evolus, Inc.
10.10. Supernus Pharmaceuticals
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES